This Article Full Text Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xue, Y. Articles by Redinbo, M. R. Search for Related Content PubMed PubMed Citation Articles by Xue, Y. Articles by Redinbo, M. R.

Crystal Structure of the Pregnane X Receptor-Estradiol Complex Provides Insights into Endobiotic Recognition

Department of Chemistry (Y.X., J.O., S.B., M.R.R.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599; Molecular Discovery Research (L.B.M.), GlaxoSmithKline, Research Triangle Park, North Carolina 27709; Department of Molecular Biology (L.P., S.A.K.), The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390; Department of Biochemistry and Biophysics (M.R.R.), and the Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599

Address all correspondence and requests for reprints to: Matthew R. Redinbo, Ph.D., Department of Chemistry, CB 3290, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3290. E-mail: redinbo{at}unc.edu.

The human nuclear pregnane X receptor (PXR) responds to a wide variety of xenobiotic and endobiotic compounds, including pregnanes, progesterones, corticosterones, lithocholic acids, and 17ß-estradiol. In response to these ligands, the receptor controls the expression of genes central to the metabolism and excretion of potentially harmful chemicals from both exogenous and endogenous sources. Although the structural basis of PXR’s interaction with small and large xenobiotics has been examined, the detailed nature of its binding to endobiotics, including steroid-like ligands, remains unclear. We report the crystal structure of the human PXR ligand-binding domain (LBD) in complex with 17ß-estradiol, a representative steroid ligand, at 2.65 Å resolution. Estradiol is found to occupy only one region of PXR’s expansive ligand-binding pocket, leaving a notable 1000 ų of space unoccupied, and to bridge between the key polar residues Ser-247 and Arg-410 in the PXR LBD. Positioning the steroid scaffold in this way allows it to make several direct contacts to AF of the receptor’s AF-2 region. The PXR-estradiol complex was compared with that of other nuclear receptors, including the estrogen receptor, in complexes with analogous ligands. It was found that PXR’s placement of the steroid is remarkably distinct relative to other members of the nuclear receptor superfamily. Using the PXR-estradiol complex as a guide, the binding of other steroid- and cholesterol-like molecules was then considered. The results provide detailed insights into the manner in which human PXR responds to a wide range of endobiotic compounds.

NURSA Molecule Pages Link:

Nuclear Receptors:   LXRβ  |  LXRα  |  PXR  |  CAR  |  GR

Coregulators:   SRC-1

Ligands:   Dexamethasone  |  Hydrocortisone  |  17β-Estradiol  |  Progesterone

This article has been cited by other articles:

				G. V. Markov, R. Tavares, C. Dauphin-Villemant, B. A. Demeneix, M. E. Baker, and V. Laudet Independent elaboration of steroid hormone signaling pathways in metazoans PNAS, July 21, 2009; 106(29): 11913 - 11918. [Abstract] [Full Text] [PDF]

				D. G. Teotico, J. J. Bischof, L. Peng, S. A. Kliewer, and M. R. Redinbo Structural Basis of Human Pregnane X Receptor Activation by the Hops Constituent Colupulone Mol. Pharmacol., December 1, 2008; 74(6): 1512 - 1520. [Abstract] [Full Text] [PDF]

				P. J. Murphy The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008 Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982. [Abstract] [Full Text] [PDF]

				S. Ekins, V. Kholodovych, N. Ai, M. Sinz, J. Gal, L. Gera, W. J. Welsh, K. Bachmann, and S. Mani Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists Mol. Pharmacol., September 1, 2008; 74(3): 662 - 672. [Abstract] [Full Text] [PDF]

				H. Wang, H. Li, L. B. Moore, M. D. L. Johnson, J. M. Maglich, B. Goodwin, O. R. R. Ittoop, B. Wisely, K. Creech, D. J. Parks, et al. The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor Mol. Endocrinol., April 1, 2008; 22(4): 838 - 857. [Abstract] [Full Text] [PDF]

				G. Lemaire, C. Benod, V. Nahoum, A. Pillon, A.-M. Boussioux, J.-F. Guichou, G. Subra, J.-M. Pascussi, W. Bourguet, A. Chavanieu, et al. Discovery of a Highly Active Ligand of Human Pregnane X Receptor: A Case Study from Pharmacophore Modeling and Virtual Screening to "In Vivo" Biological Activity Mol. Pharmacol., September 1, 2007; 72(3): 572 - 581. [Abstract] [Full Text] [PDF]

				S. Ekins, C. Chang, S. Mani, M. D. Krasowski, E. J. Reschly, M. Iyer, V. Kholodovych, N. Ai, W. J. Welsh, M. Sinz, et al. Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites Mol. Pharmacol., September 1, 2007; 72(3): 592 - 603. [Abstract] [Full Text] [PDF]